Viking Therapeutics Announces Positive Financial Results and Clinical Pipeline Update

Important Developments

Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLD Positive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma Lipids Strong Quarter-End Cash Position of $930 Million SAN DIEGO , Oct. 23, 2024 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2024, and provided an update on its clinical pipeline and other corporate developments.

Impact on Individuals

Individuals who are suffering from metabolic and endocrine disorders may benefit from the innovative therapies being developed by Viking Therapeutics. These new treatments have the potential to improve quality of life and provide hope for those in need of effective solutions.

Global Impact

Viking Therapeutics’ advancements in the field of biopharmaceuticals have the potential to have a significant global impact. By developing novel therapies for metabolic and endocrine disorders, Viking is contributing to the advancement of medical science and offering new treatment options to patients worldwide.

Conclusion

With a strong financial position and promising developments in its clinical pipeline, Viking Therapeutics is poised for continued success in the biopharmaceutical industry. The company’s dedication to innovation and improving patient outcomes is commendable, and the future looks bright for both individuals in need of treatment and the global healthcare community as a whole.